Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes
European Journal of Drug Metabolism and Pharmacokinetics · 2024-09 · 49 (5) · 583-594
DOI: 10.1007/s13318-024-00903-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, online erschienen am 24.06.2024. Verfasst von Fawzy A Elbarbry und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Pacific University, 222 SE 8th Ave., Hillsboro, OR, 97123, USA. Fawzy.elbarbry@pacificu.edu. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Coumarins, Molecular Docking Simulation, Cytochrome P-450 Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Both AW-9A (coumarin derivative) and WES-1 (sulfonamide derivative) were designed and synthesized as potential selective carbonic anhydrase inhibitors and were tested for anticancer activity. This study was undertaken to investigate their potential inhibitory effects on the major human cytochrome P450 (CYP) drug-metabolizing enzymes. METHODS: Specific CYP probe substrates and validated analytical methods were used to measure the activity of the tested CYP enzymes. Furthermore, in silico simulations were conducted to understand how AW-9A and WES-1 bind to CYP2A6 at a molecular level. Molecular docking experiments were performed using the high-resolution X-ray structure, Protein Data Bank (PDB) ID: 2FDV for CYP2A6. RESULTS: CYP2E1-catalyzed chlorzoxazone-6'-hydroxylation was strongly inhibited by AW-9A and WES-1 with IC50 values of 0.084 µM and 0.101 µM, respectively. CYP2A6-catalyzed coumarin-7'-hydroxylation was moderately inhibited by AW-9A (IC50 = 4.2 µM). CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 enzymes were weakly or negligibly inhibited by both agents. Docking studies suggest elevated potential to block the catalytic activity of CYP2A6. CONCLUSIONS: These findings point to the feasibility of utilizing these agents as promising chemopreventive agents (owing to inhibition of CYP2E1), and AW-9A as a smoking cessation aid (owing to inhibition of CYP2A6). Additional in-vivo studies should be conducted to examine the impact of CYP2A6 and CYP2E1 inhibition on drug interactions with probe substrates of these enzymes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Pacific University, 222 SE 8th Ave., Hillsboro, OR, 97123, USA. Fawzy.elbarbry@pacificu.edu.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, P.O. Box 33516, Kafrelsheikh, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, 11829, Egypt.
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019, Sesto Fiorentino, Firenze, Italy.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University, Alexandria, Egypt.
Zitieren
APA
Elbarbry, F. A., Ibrahim, T. M., Abdelrahman, M. A., Supuran, C. T., & Eldehna, W. M. (2024). Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics, 49(5), 583-594. https://doi.org/10.1007/s13318-024-00903-6
Vancouver
Elbarbry FA, Ibrahim TM, Abdelrahman MA, Supuran CT, Eldehna WM. Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics. 2024;49(5):583-594. doi:10.1007/s13318-024-00903-6
BibTeX
@article{Elbarbry2024,
author = {Elbarbry, Fawzy A and Ibrahim, Tamer M and Abdelrahman, Mohamed A and Supuran, Claudiu T and Eldehna, Wagdy M},
title = {Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes},
journal = {European Journal of Drug Metabolism and Pharmacokinetics},
year = {2024},
volume = {49},
number = {5},
pages = {583--594},
doi = {10.1007/s13318-024-00903-6}
}
EUVIMED